NCT00644033 - A Randomized Trial of Frovatriptan for the Intermittent Prevention of Menstrual Migraine | Biotech Hunter

Enrollment

579

Participants

Timeline

Start Date

June 30, 2001

Primary Completion Date

June 30, 2002

Study Completion Date

June 30, 2002

Conditions

Menstrually Associated Migraine

Interventions

DRUG

Frovatriptan

2.5 mg tablet administered once daily for 6 days starting 2 days before the anticipated onset of a MAM headache

DRUG

Frovatriptan

2.5 mg tablet administered twice daily for 6 days, starting 2 days before the anticipated onset of a MAM headache.

DRUG

Placebo

placebo tablet administered for 6 days, starting 2 days before the anticipated onset of a MAM headache.

Trial Locations (1)

Endo Pharmaceuticals, Chadds Ford